Monday . . . .
Tuesday . . . .
Wednesday . .
Thursday. . . .
Friday. . . . . . Others by appt.
Biographical Information:Paul Harding is a molecular and cellular biologist who is interested elucidating the in vivo roles of heparin-binding EGF-like growth factor (HB-EGF). HB-EGF is a member of the epidermal growth factor (EGF) family and is a potent mitogen and chemotactic factor for epithelial cells, fibroblasts, and smooth muscle cells. HB-EGF binds to and activates the EGF receptor (HER1) as well as at least one EGFR subtype (HER4). HB-EGF is synthesized as a membrane-bound protein that undergoes shedding to yield a soluble form. HB-EGF has been implicated both in pathological processes and normal physiological processes such as:
Tumor formation, Atherosclerosis, Wound healing
Dr. Hardings research group utilizes molecular techniques in order to assess HB-EGF activity including DNA cloning, mammalian tissue culture, Western, Southern, and Northern Blotting, DNA sequencing, and DNA mutagenesis. Currently, our group is developing both an HB-EGF transgenic mouse and an HB-EGF Knock-In mouse using the cre-loxp methodology.